Natera Presents New Colorectal and Breast Cancer Data at ESMO

  Natera Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France.

Signatera data was presented in 4 abstracts, including both oral and poster presentations. These include results from a real-world study on colorectal cancer (CRC) patients as well as an early readout from the BELLINI trial that highlights how circulating tumor DNA (ctDNA) dynamics can help inform neoadjuvant treatment decision-making in hormone receptor negative, HER2 negative (triple-negative) breast cancer (TNBC).

https://www.biospace.com/article/releases/natera-presents-new-colorectal-and-breast-cancer-data-at-esmo-2022-highlighting-signatera-s-ability-to-inform-treatment-decisions-in-the-adjuvant-and-neoadjuvant-settings/